Heat Biologics announced that a new development is underway in the company’s partnership with subsidiary Scorpion Biological Services.
Roche partnered with Bristol Myers Squibb to utilize two digital pathology platforms that would advance research into treatment options for patients diagnosed to have solid tumors.
Amgen Chief Executive Officer Robert Bradway is excited about 2022. During his presentation at the J.P. Morgan Healthcare Conference, Bradway said things are lining up for long-term growth for the California-based company.
Roche and Atea Pharmaceuticals are terminating their partnership to develop and commercialize a Covid-19 antiviral effective February 10, 2022.
Bayer terminated a vaccine manufacturing partnership under which the company would have helped produce CureVac’s Covid-19 shot, a spokesperson for Bayer told a German newspaper.
Fresh out of the gates with $500 million in financing, neuroscience-focused Neumora Therapeutics forged a strategic partnership with Amgen to develop and commercialize assets owned by the pharma giant, targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases.
One week after launching a dedicated CRISPR program, Qiagen partnered with San Diego-based Verogen to provide next-generation sequencing human identification workflows to laboratories in order to support forensic efforts from justice departments across the globe.
GlaxoSmithKline will lay out plans to boost the spending power of the company’s research-focused pharmaceuticals business at an investor day on June 23, as analysts call on the British drugmaker to boost drug development prospects with takeovers or alliances.
EVERSANA, a pioneer in next generation commercialization services to the global life sciences industry, announced a partnership with thenetworkone, the world’s largest independent marketing and communications agency network. Through the agreement, EVERSANA’s full-solutions healthcare marketing agency, EVERSANA ENGAGE, strengthens its global marketing capabilities across 115 countries through an ecosystem of more than 1,200 leading agencies worldwide.
Vir Biotechnology and GlaxoSmithKline plan to seek emergency use authorization for their experimental Covid-19 antibody therapy after interim data from a study showed 85 percent reduction in hospitalization and deaths among patients.